New research from Biognosys and collaborators, presented at the 2021 ASCO and AACR conferences, shows how next-generation proteomics can help to predict both outcomes and adverse events from immunotherapy.
Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types.
In recent years, the field of proteomics has undergone a transformation, enabling quantitative analysis of more than 10,000 proteins across thousands of samples, while advances in structural chemoproteomics allow researchers to map drug binding sites with unprecedented resolution. These next-generation proteomics approaches are driving significant progress in precision oncology.
A recent study demonstrated a significant increase in pregnancy and live birth rates associated with the use of artificial intelligence-assisted genetic testing technology alongside in vitro fertilization.
The COVID-19 pandemic has caused massive disruption to cancer care. Delays in diagnosis and treatment highlight the importance of establishing a personalized healthcare approach that provides tailored care, integrates innovation, and supports equal access to cancer care.
As America’s first repository of microorganisms and other biomaterials, ATCC has a steeped history as one of the pillars of infectious disease research. Recognizing that many researchers are just now getting back to the lab, the organization is sharing what it has learned over the past several months about best practices for keeping workers safe.
Advances in quantitative proteomics have great potential to improve cancer research and treatment by uncovering and validating novel drug targets, helping to understand drug mechanisms of action, and searching for new diagnostic, prognostic, or predictive biomarkers.
Several examples of this innovation were on display at the recent American Association for Cancer Research Virtual Annual Meeting, where Biognosys published seven posters highlighting the utility of its next-generation proteomics platform in oncology.
Researchers worldwide are racing to address COVID-19, working on diagnostics, therapies, and vaccines to control the virus. To support these efforts, DDL Diagnostic Laboratory is developing faster ways to identify viral genomic variants – work that was accelerated by a collaboration with bioinformatics provider Seven Bridges.